DE69901051D1 - Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten - Google Patents

Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten

Info

Publication number
DE69901051D1
DE69901051D1 DE69901051T DE69901051T DE69901051D1 DE 69901051 D1 DE69901051 D1 DE 69901051D1 DE 69901051 T DE69901051 T DE 69901051T DE 69901051 T DE69901051 T DE 69901051T DE 69901051 D1 DE69901051 D1 DE 69901051D1
Authority
DE
Germany
Prior art keywords
phosphate
guggul extract
composition
compositions containing
phosphate salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69901051T
Other languages
English (en)
Inventor
William Desisles Brink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolab Nutrition Inc
Original Assignee
Prolab Nutrition Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolab Nutrition Inc filed Critical Prolab Nutrition Inc
Application granted granted Critical
Publication of DE69901051D1 publication Critical patent/DE69901051D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69901051T 1998-10-27 1999-10-27 Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten Expired - Lifetime DE69901051D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/179,328 US6113949A (en) 1998-10-27 1998-10-27 Weight control product and method of treating hyperlipidemia and increasing vigor with said product

Publications (1)

Publication Number Publication Date
DE69901051D1 true DE69901051D1 (de) 2002-04-25

Family

ID=22656113

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69901051T Expired - Lifetime DE69901051D1 (de) 1998-10-27 1999-10-27 Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten

Country Status (6)

Country Link
US (1) US6113949A (de)
EP (1) EP0997149B1 (de)
AT (1) ATE214613T1 (de)
CA (1) CA2267488A1 (de)
DE (1) DE69901051D1 (de)
GB (1) GB2343115A (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6896901B2 (en) * 2000-12-22 2005-05-24 Council Of Scientific & Industrial Research Method of treating a cognitive memory dysfunction using Gugulipid
US6485710B2 (en) * 2000-12-27 2002-11-26 Arthur Zuckerman Appetite suppressant toothpaste
US6610277B2 (en) * 2000-12-27 2003-08-26 Arthur Zuckerman Appetite suppressant toothpaste
EP1238590A1 (de) * 2001-03-09 2002-09-11 Unilever N.V. Nahrungsmittelprodukt auf der Basis von Fett
EP1390051A2 (de) * 2001-05-29 2004-02-25 Unilever Plc Lebensmittelzusammensetzungen zur verminderung der insulinresistenz
US6849278B2 (en) * 2001-11-21 2005-02-01 Universal Biotech Co., Ltd. Method to counter oxidation of LDL, decrease triglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract
US6852342B2 (en) * 2002-03-26 2005-02-08 Avoca, Inc. Compounds for altering food intake in humans
AU2003228603A1 (en) * 2002-04-22 2003-11-10 Rtc Research And Development, Llc. Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals
WO2003092614A2 (en) * 2002-05-02 2003-11-13 Hickle Randall S Lipid removal from the body
US6565896B1 (en) * 2002-07-03 2003-05-20 Vitacost.Com, Inc. Cholesterol treatment formulation
US20040253327A1 (en) * 2003-06-12 2004-12-16 Niazi Sarfaraz K. Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides, and sugar and preventing or treating cardiovascular diseases
US20050025844A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Weight control compositions and methods
US20050163872A1 (en) * 2004-01-23 2005-07-28 Cargill, Incorporated Compositions and methods for reducing cholesterol
WO2006017211A1 (en) * 2004-07-12 2006-02-16 Research Development Foundation Guggulsterone as an inhibitor of nuclear factor-kb and ikbalpha kinase activation
FR2876912B1 (fr) * 2004-10-25 2007-04-20 Nuxe Sa Lab Nouvelle utilisation de guggulipides en therapeutique et en cosmetique
ATE451911T1 (de) * 2004-10-22 2010-01-15 Nuxe Lab Neuartige verwendung von chaulmoogra-öl und guggulipiden in therapeutika und kosmetika
US8287924B2 (en) 2011-03-17 2012-10-16 Sonia Pharma Gmbh Treatment of menopausal symptoms as novel indication for myrrh

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117120A (en) * 1977-02-11 1978-09-26 Elderbaum Gilbert J Medication for herpes simplex and canker sores
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4592912A (en) * 1983-10-31 1986-06-03 Harriet Nickolaus Ache and pain relieving and preventing composition
US4719111A (en) * 1985-06-14 1988-01-12 Wilson Lynn M Novel composition for treatment of decubitus ulcers
US4713242A (en) * 1985-11-07 1987-12-15 Tecma Laboratories, Inc. Skin therapeutic mixture containing eupatorium extract
US4847071A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US4847069A (en) * 1987-10-22 1989-07-11 The Procter & Gamble Company Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
DK339289D0 (da) * 1989-07-07 1989-07-07 Dak Lab As Farmaceutisk praeparat
JPH0366623A (ja) * 1989-08-03 1991-03-22 Toreede Uindo Kk 肥満防止剤及びその製造法
EP0447706A1 (de) * 1990-03-22 1991-09-25 Cipla Limited Verfahren zur Herstellung einer pharmazeutischen aktiven Mischung der Guggulsteronen Z und E
IT1247933B (it) * 1991-05-15 1995-01-05 Indena Spa Estratti di commiphora mukul e loro applicazioni terapeutiche
US5238965A (en) * 1991-05-31 1993-08-24 The Procter & Gamble Company Methods of using lysophosphatidic acids for regulating skin wrinkles
US5104676A (en) * 1991-06-27 1992-04-14 Abbott Laboratories Weight control product
AU3073792A (en) * 1991-11-25 1993-06-28 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
EP0695181A1 (de) * 1993-04-20 1996-02-07 The Procter & Gamble Company Verfahren zur verwendung von hesperetin zur sebumreduktion und behandlung von akne
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
JP3396542B2 (ja) * 1994-07-22 2003-04-14 株式会社成幸社 固形上の痩身用食品
US5690948A (en) * 1997-01-10 1997-11-25 Elizabeth Arden Co., Division Of Conopco, Inc. Antisebum and antioxidant compositions containing guguliped and alcoholic fraction thereof

Also Published As

Publication number Publication date
EP0997149B1 (de) 2002-03-20
EP0997149A1 (de) 2000-05-03
CA2267488A1 (en) 2000-04-27
GB9907037D0 (en) 1999-05-19
US6113949A (en) 2000-09-05
GB2343115A (en) 2000-05-03
ATE214613T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
ATE214613T1 (de) Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten
Harker et al. Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates.
Basu et al. Intestinal absorption in health and disease: micronutrients
AU3955089A (en) Pharmaceutical composition comprising protein kinase c inhibitor and anti-cancer agent
CA2229077A1 (en) Lipid metabolism improving agent
DE69122099T2 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
ATE254404T1 (de) Mehrteiliges nahrungsmittel, verfahren zu dessen herstellung und verwendung desselben
BR0013157A (pt) Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna
Cheng et al. High levels of dietary vitamin E do not replace cellular glutathione peroxidase in protecting mice from acute oxidative stress
ATE293367T1 (de) Nahrungszusammensetzungen enthaltend methionin
ATE129894T1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
CA2078019A1 (en) Substance or composition and uses thereof
AU2002224240A1 (en) Colostrum-based composition
Fullmer Intestinal calcium and lead absorption: effects of dietary lead and calcium
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
WO2003020233A3 (de) Stabilisierung uv-empfindlicher wirkstoffe
WO2001005356A3 (en) Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
BR9914644A (pt) Composições tamponadas para diálise
de Jong et al. Hyperhomocysteinemia and atherothrombotic disease
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
JP2020528888A (ja) 心血管器官の病態の予防及び処置における使用のための組成物
GB2210789A (en) Topical application for skin care
PL1660097T3 (pl) Kompozycja fizjologicznie czynna na bazie fosfatydyloseryny
Suja et al. Protective effect of Liv. 52 and Liv. 100, ayurvedic formulations on lipid peroxidation in rat liver homogenate-an in vitro study
BR0313651A2 (pt) composiÇço para administraÇço oral ou rectal

Legal Events

Date Code Title Description
8332 No legal effect for de